非肌层浸润性膀胱癌膀胱灌注治疗专家共识(2021版)
膀胱癌是我国常见恶性肿瘤,75%为非肌层浸润性且术后复发率高,膀胱灌注治疗可降低复发和进展风险。本共识在2019版基础上,结合国内外循证医学证据与国内临床实践,更新了危险度评估、灌注药物选择、不良反应处理及新型药物临床研究等内容,为国内规范化膀胱灌注治疗提供指导。
要点
- 75%的膀胱癌为非肌层浸润性,术后复发率高。
- 膀胱灌注细胞毒性药物或免疫制剂可降低复发和进展风险。
- 共识更新了危险度评估、药物选择及不良反应处理等内容。
核心结论
- 本共识为2021版更新,旨在指导国内非肌层浸润性膀胱癌膀胱灌注的规范化治疗。
研究设计与样本
- 由中国肿瘤医院泌尿肿瘤协作组在2019版专家共识基础上制定,结合国内外循证医学证据与国内临床实践和经验。
主要发现
- 临床上75%的膀胱癌为非肌层浸润性膀胱癌,术后复发率高。
- 膀胱灌注治疗通过注入细胞毒性药物直接杀伤肿瘤细胞,或注入免疫制剂如卡介苗直接或间接诱导局部免疫反应,降低肿瘤复发和进展风险。
- 近年来国内外在非肌层浸润性膀胱癌的危险度评估、灌注药物选择、不良反应及处理经验、新型灌注药物临床研究等方面取得较大进展。
临床怎么用
- 依据共识对非肌层浸润性膀胱癌进行危险度评估、灌注药物选择及不良反应处理,以规范化膀胱灌注治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bladder cancer is one of the common malignant tumors in China, with 75% of bladder cancer being non-muscle invasion with a high recurrence rate after surgery. Intravesical therapy is an useful methods to either directly kill tumor cells by infusing cytotoxic drugs into the bladder or directly or indirectly induce local immune responses of the body through infusing immune agents, such as bacillus calmette guerin, and thus reduce the risk of tumor recurrence and progression. In 2019, the Urological Chinese Oncology Group issued the "Expert consensus on intravesical therapy on non-muscle invasive bladder cancer" . Recently, great progress in the clinical diagnosis and treatment of non-muscle invasive bladder cancer has been achieved domestically and abroad, including the risk assessment of non-muscle invasive bladder cancer, the therapeutic choice of intravesical drugs, the adverse reactions and treatment experience of intravesical therapy, and clinical research on new types of intravesical drugs. This consensus is made according to domestic and overseas evidence-based medicine in combination with current clinical practice and experience of intravesical therapy for non-muscle invasive bladder cancer in China. It is an update of the 2019 expert consensus, with the wish to provide a guidance for domestic clinical standardized intravesical therapy for non-muscle invasive bladder cancer. 膀胱癌是我国居民常见的恶性肿瘤之一,临床上75%的膀胱癌为非肌层浸润性膀胱癌,术后复发率高。膀胱灌注治疗是向膀胱内注入细胞毒性药物直接杀伤肿瘤细胞,或注入免疫制剂如卡介苗等直接或间接诱导体内发生局部免疫反应,从而降低肿瘤复发和进展的风险。2019年中国肿瘤医院泌尿肿瘤协作组发布了非肌层浸润性膀胱癌膀胱灌注治疗专家共识。近年来,国内外非肌层浸润性膀胱癌的临床诊治有了较大进展,包括非肌层浸润性膀胱癌的危险度评估,膀胱灌注药物的选择,膀胱灌注的不良反应及处理经验以及新型膀胱灌注药物的临床研究等。共识根据国内外循证医学证据,结合目前国内非肌层浸润性膀胱癌膀胱灌注治疗的临床实践和应用经验,在2019版专家共识的基础上进行了相应的探讨和更新,以期对目前国内非肌层浸润性膀胱癌膀胱灌注的临床规范化治疗提供一定指导意见。.
引用
- [Expert consensus on intravesical therapy for non-muscle invasive bladder cancer (2021 edition)]. Zhonghua Zhong Liu Za Zhi. 2021. PMID: 34695892. doi:10.3760/cma.j.cn112152-20210811-00605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。